Perifosine (KRX-0401)

Name: Perifosine (KRX-0401)
Brand: Selleck Chemicals
SKU: S1037
Rating: 5 (145 reviews)

For research use only.

Catalog No.S1037 Synonyms: NSC639966, D21266

145 publications

Perifosine (KRX-0401) Chemical Structure

CAS No. 157716-52-4

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Selleck's Perifosine (KRX-0401) has been cited by 145 publications

Cancer Cell, 2013, 23(6):839-52

PubMed: 23684459 ( click the link to review the publication )

Cell, 2012, 149(3):656-70

PubMed: 22920938 ( click the link to review the publication )

Aging (Albany NY), 2020, 18;12(10):9489-9499

PubMed: 32421688 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa159

PubMed: 33078829 ( click the link to review the publication )

Front Microbiol, 2020, 11:565590

PubMed: 33042070 ( click the link to review the publication )

Cancer Cell Int, 2020, 25;20:134

PubMed: 32351328 ( click the link to review the publication )

J Cell Biochem, 2020, 121(1):723-734

PubMed: 31452248 ( click the link to review the publication )

Transl Oncol, 2020, 13(2):355-364

PubMed: 31887630 ( click the link to review the publication )

Cell Stress Chaperones, 2020, 9

PubMed: 32519137 ( click the link to review the publication )

Chin J Integr Med, 2020, 10.1007

PubMed: 31903532 ( click the link to review the publication )

Commun Biol, 2020, 3(1):378

PubMed: 32665601 ( click the link to review the publication )

Sci Rep, 2020, 10(1):10315

PubMed: 32587277 ( click the link to review the publication )

Biosci Rep, 2020, BSR20201539

PubMed: 33269380 ( click the link to review the publication )

Dev Cell, 2019, 50(2):229-246

PubMed: 31204173 ( click the link to review the publication )

Dev Cell, 2019, 51(2):236-254

PubMed: 31543445 ( click the link to review the publication )

Cancer Lett, 2019, 447:93-104

PubMed: 30660646 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5334

PubMed: 31397884 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31769426 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627436 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(2):356-363

PubMed: 30446585 ( click the link to review the publication )

Cell Prolif, 2019, 52(5):e12638

PubMed: 31152465 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28205

PubMed: 30706473 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31850228 ( click the link to review the publication )

Front Oncol, 2019, 9:422

PubMed: 31192127 ( click the link to review the publication )
Sci Rep, 2019,

PubMed: 31767884 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 381:114729

PubMed: 31445927 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.28410

PubMed: 30724378 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(3):559-565

PubMed: 30824188 ( click the link to review the publication )

Mol Med Rep, 2019, 20(1):33-40

PubMed: 31115502 ( click the link to review the publication )

Med Sci Monit, 2019, 25:7218-7227

PubMed: 31554782 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):911

PubMed: 30185800 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):747

PubMed: 29970878 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):739

PubMed: 29970892 ( click the link to review the publication )

Front Aging Neurosci, 2018, 10:378

PubMed: 30515090 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

J Cell Biochem, 2018, 119(12):9997-10004

PubMed: 30145830 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(11):1219-1229

PubMed: 30265530 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(8):748-756

PubMed: 29961813 ( click the link to review the publication )

BMC Neurosci, 2018, 19(1):52

PubMed: 30189852 ( click the link to review the publication )

Cell Biol Int, 2018, 42(8):959-964

PubMed: 29569784 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):447-454

PubMed: 29749519 ( click the link to review the publication )

Transl Cancer Res, 2018, 7(6):1548-1560

PubMed: 30761266 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9425-9441

PubMed: 29507700 ( click the link to review the publication )

Oncotarget, 2018, 9(15):12261-12272

PubMed: 29552308 ( click the link to review the publication )

J Pharm Pharmacol, 2018, 70(2):259-267

PubMed: 29148068 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(3):238-251

PubMed: 28218907 ( click the link to review the publication )

Nat Commun, 2017, 8:14091

PubMed: 28345588 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )
Sci Rep, 2017, 7:45136

PubMed: 28332584 ( click the link to review the publication )

Am J Pathol, 2017, 187(8):1736-1749

PubMed: 28627412 ( click the link to review the publication )

Mediators Inflamm, 2017, 2017:5706152

PubMed: 29056830 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169585

PubMed: 28081222 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0173473

PubMed: 28291820 ( click the link to review the publication )

Med Sci Monit, 2017, 23:5637-5649

PubMed: 29176544 ( click the link to review the publication )

Biotechnol Lett, 2017, 39(9):1343-1349

PubMed: 28597147 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(9):9400-9408

PubMed: 31966812 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63911-63922

PubMed: 28969040 ( click the link to review the publication )

Sci Rep, 2017, 7:42062

PubMed: 28165023 ( click the link to review the publication )

Oncotarget, 2017, 8(2):2594-2603

PubMed: 27911877 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(4):1300-10

PubMed: 26927669 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(6):3130-3145

PubMed: 27980063 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2043

PubMed: 26775697 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1504-14

PubMed: 27196761 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:305-313

PubMed: 27665476 ( click the link to review the publication )

Exp Cell Res, 2016, 340(1):81-90

PubMed: 26712518 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(1):54-60

PubMed: 27614310 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(4):1170-6

PubMed: 27073162 ( click the link to review the publication )

J Mol Neurosci, 2016, 59(4):567-78

PubMed: 27412469 ( click the link to review the publication )

Anticancer Res, 2016, 36(11):5849-5858

PubMed: 27793908 ( click the link to review the publication )

NPJ Syst Biol Appl, 2016, 2:16027

PubMed: 28725479 ( click the link to review the publication )
Tumour Biol, 2016, 37(1):1025-33

PubMed: 26269112 ( click the link to review the publication )

Oncotarget, 2016, 7(16):22687-99

PubMed: 27007150 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.04.015

PubMed: 25934232 ( click the link to review the publication )

Sci Rep, 2015, 5:12059

PubMed: 26154270 ( click the link to review the publication )

Oncol Rep, 2015, 33(2):875-84

PubMed: 25484022 ( click the link to review the publication )

Mol Cell Biochem, 2015, 398(1-2):105-13

PubMed: 25223639 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3244-2

PubMed: 25697899 ( click the link to review the publication )

Oncoscience, 2015,

PubMed: ( click the link to review the publication )

Oncoscience, 2015, 2(4):382-94

PubMed: 26097872 ( click the link to review the publication )

Oncoscience, 2015, 2(4):395-409

PubMed: 26097873 ( click the link to review the publication )

Oncotarget, 2015, 6(9):6597-610

PubMed: 25788264 ( click the link to review the publication )

Oncoscience, 2015, 10.1155/2015/8332

PubMed: ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015,

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(30):29963-74

PubMed: 26298773 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.184.

PubMed: 24998847 ( click the link to review the publication )

FASEB J, 2014, 27(7):2584-99

PubMed: 23507869 ( click the link to review the publication )

Cardiovasc Diabetol, 2014, 35(7):450-4

PubMed: 24836459 ( click the link to review the publication )

Carcinogenesis, 2014, 35(10):2232-43

PubMed: 24942865 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(9):1851-64

PubMed: 24769208 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )
Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Pediatr Res, 2014, 75(4):527-34

PubMed: 24366516 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:568693

PubMed: 25309914 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 450(1):646-51

PubMed: 24946212 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):362-7

PubMed: 25264192 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(1):72-8

PubMed: 25152399 ( click the link to review the publication )

Vet J, 2014, 201(1):83-90

PubMed: 24881508 ( click the link to review the publication )

Cell Logist, 2014, 4(1):e27732

PubMed: 24843827 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Rostock University, 2014, Lange F

PubMed: ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Lett, 2013, 336(2):319-24

PubMed: 23528835 ( click the link to review the publication )

Gynecol Oncol, 2013, 131(1):207-12

PubMed: 23877012 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1831(8):1322-34

PubMed: 23707264 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1828(5):1384-9

PubMed: 23376656 ( click the link to review the publication )

Sci Rep, 2013, 3:1697

PubMed: 23603888 ( click the link to review the publication )

J Biol Chem, 2013, 288(31):22836-48

PubMed: 23788636 ( click the link to review the publication )

Mol Pharmacol, 2013, 84(4):562-71

PubMed: 23877009 ( click the link to review the publication )

Biochimie, 2013, 101:50-9

PubMed: 24394624 ( click the link to review the publication )

Oncol Rep, 2013, 29(6):2422-30

PubMed: 23588929 ( click the link to review the publication )

Biochemistry, 2013, 53(3):462-72

PubMed: 24383815 ( click the link to review the publication )
Dig Dis Sci, 2013, 58(10):2873-80

PubMed: 23912246 ( click the link to review the publication )

PLoS One, 2013, 8(5):e61896

PubMed: 23658701 ( click the link to review the publication )

PLoS One, 2013, 8(8): e74420

PubMed: 24009772 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70804

PubMed: 23936469 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 443(2):447-52

PubMed: 24316214 ( click the link to review the publication )

Mol Biol Rep, 2013, 40(10):5645-55

PubMed: 24065522 ( click the link to review the publication )

Mol Med Rep, 2013, 7(2):642-8

PubMed: 23175237 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 65(2):217-27

PubMed: 23015227 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 66(3):737-46

PubMed: 23397419 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(10):2622-33

PubMed: 22461507 ( click the link to review the publication )

J Clin Endocrinol Metab, 2012, 97(2):E173-82

PubMed: 22090271 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(12):1898-912

PubMed: 23001822 ( click the link to review the publication )

J Biol Chem, 2012, 286(43):37389-98

PubMed: 21908616 ( click the link to review the publication )

Expert Opin Inv Drugs, 2012, 21(11):1597-606

PubMed: ( click the link to review the publication )

Mol Carcinog, 2012, 52(9):667-75

PubMed: 22488590 ( click the link to review the publication )

Surgery, 2012, 152(6):1218-24

PubMed: 23158188 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(11):1009-17

PubMed: 22825337 ( click the link to review the publication )

PLoS Biol, 2011, 9(9):e1001148

PubMed: 21931533 ( click the link to review the publication )

Cancer Lett, 2011, 310(1):118-28

PubMed: 21775054 ( click the link to review the publication )

J Pharmacol Exp Ther, 2011, 336(3):866-73

PubMed: 21148684 ( click the link to review the publication )

Radiat Oncol, 2011, 6:39

PubMed: 21496273 ( click the link to review the publication )

Cancer Res, 2010, 70(22):9106-17

PubMed: 21062988 ( click the link to review the publication )

Brit J Pharmacol, 2010, 160(2):355-66

PubMed: 20423345 ( click the link to review the publication )
Cytotechnology, 2010, 62(5):449-60

PubMed: 20842425 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Targets

Akt ^[1]
(MM.1S cells)

4.7 μM

In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. ^[1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. ^[2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. ^[3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
T24 BC	NXTKeZBKTnWwY4Tpc44hSXO\|YYm=	MmL6NE42NzFxMj61JO69VQ>?	M4ThUlMhcA>?	NFjlSJlz\WS3Y3XzJJRp\SCkYYPhcEBESiC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NUnodoFNOjZyOUe4O\|M>
T24 BC	M3\Z[WNmdGxiVnnhZoltcXS7IFHzd4F6	MX:wMlUwOS9{LkWg{txO	MnXPNlQhcA>?	NYjMOopO\W6qYX7j[ZMhe2:{YX\lcoljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImg[IVkemWjc3W=	NFPJOoYzPjB7N{i3Ny=>
T24 BC	NHLtN5JCeG:ydH;zbZMhSXO\|c3H5	NVzRTmhpOi53IN88US=>	Mo\VNlQhcA>?	M{PRe5NmdnOrdHn6[ZMhSkNiY3XscJMhfG9ic3;yZYZmdmmkLXnu[JVk\WRiYYDvdJRwfGmlwrC=	NWXsfItoOjZyOUe4O\|M>
HepG2	NXPvfGRYTnWwY4Tpc44hSXO\|YYm=	NEDoO\|AzOMLizszN	M{H6[\|I1yqCq	NXnrUIJHeHKxZIXj[ZMh[W5iaX70[Y5{\SCleYTvdIxie22rYzD2ZYN2d2yrenH0bY9vKGOxcoLld5BwdmSrbnegeI8h[SCwb4ThZoxmKGSrbHH0ZZRqd25ib3[geIhmKEWUIHPpd5Rmem6\|	M{XEPFI2QTN2MkOy
U-87 MG	NVPGRodXTnWwY4Tpc44hSXO\|YYm=	NYPabIxlOjEEoN88US=>	NWLTXHgyOjUEoHi=	NHLZUJBqdmO{ZXHz[ZMh\G:3YnzlMY1mdWK{YX7lJIJwfW6mIIP0dpVkfHW{ZYO=	M2L6elI2QTN2MkOy
HepG2	MYrGeY5kfGmxbjDBd5NigQ>?	NH;KVFUzOMLizszN	MXO2M\|I1KGh?	MlvWbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS	NIjId\|czPTl\|NEKzNi=>
U-87 MG	M1jYdGZ2dmO2aX;uJGF{e2G7	NHPZZXgzOMLizszN	NFzSPIs3NzJ2IHi=	M3HGTolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFzDN{1KUSClb4Ty[YF1\WRid3n0bEBEWQ>?	M1X0WFI2QTN2MkOy
HepG2	NXS0WmMzTnWwY4Tpc44hSXO\|YYm=	MYOyNOKh\|ryP	NV;GO3MxPi9{NDDo	MYrk[YNz\WG\|ZYOgUGM{NUmLIHTl[5Ji\GG2aX;uxsBnem:vIE[gbC=>	NWD4NYFlOjV7M{SyN\|I>
U-87 MG	NVW5[\|U4TnWwY4Tpc44hSXO\|YYm=	MYGyNOKh\|ryP	MoezOk8zPCCq	NYG0c5V5cW6lcnXhd4V{KHSqZTDheZRweGijZ3njJIZtfXhiIHH0JFYhcCC5aHns[UBqdmirYnn0d{B1cGm\|IH\seZgh[XRiMkTo	MXOyOVk{PDJ\|Mh?=
HepG2	NF;Ic4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELSfI8zOC92MDFOwG0>	MWiyOE81QCCq	NFHyUGJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NVO1SIxuOjV7M{SyN\|I>
U-87 MG	Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnDNlAwPDBizszN	MojuNlQwPDhiaB?=	NXzLdog3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M134T\|I2QTN2MkOy
A549	M4jJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HoW\|AvOy1zMDFOwG0>	NVTROlVOOjRxN{KgbC=>	MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NY[xPZRTOjV4OUe4PVk>
H460	NHiyRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLWbJgxNjNvMUCg{txO	MVmyOE84OiCq	NYX6bVVjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MYqyOVY6Pzh7OR?=
A549	MYrBdI9xfG:\|aYOgRZN{e2G7	NU\UblJYOS9\|IN88US=>	Mnu3OFghcA>?	MnfpbY5lfWOnczDhdI9xfG:\|aYO=	MWmyOVY6Pzh7OR?=
H460	M13rNGFxd3C2b4Ppd{BCe3O\|YYm=	M{DE[\|EwOyEQvF2=	NUTMdpJGPDhiaB?=	MnrWbY5lfWOnczDhdI9xfG:\|aYO=	NWnaXopxOjV4OUe4PVk>
A549	M{nJPGZ2dmO2aX;uJGF{e2G7	M3nVOFMh\|ryP	NEDIXZE5KGh?	NFXifmJjdG:la4OgRWtVKGGldHn2ZZRqd25?	MkDUNlU3QTd6OUm=
H460	NWex[otjTnWwY4Tpc44hSXO\|YYm=	NITV[pk{KM7:TR?=	M4rDSlghcA>?	M1LTeYJtd2OtczDBT3Qh[WO2aY\heIlwdg>?	NXHWeWpWOjV4OUe4PVk>
A549	NXHPb3FETnWwY4Tpc44hSXO\|YYm=	MojhN{DPxE1?	NWDpbJZ5QCCq	Mon6Zoxw[2u\|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{	NVnyPVd6OjV4OUe4PVk>
H460	NF60RmNHfW6ldHnvckBCe3OjeR?=	MnH3N{DPxE1?	NXLGXmRGQCCq	M3rzfIJtd2OtczDtWG9TSzFuIHHu[EBGWktvTVHQT{Bi[3SrdnH0bY9vKGOxbXLpcoVlKHerdHigUWVMNTF4Mh?=	MoG1NlU3QTd6OUm=
RMG1	MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NXfNeHBmOS1\|MDFOwG0>	MojKO\|IhcA>?	MkX2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	M{Dl[FI2PTF7MUS4
RMG2	MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2GyWVEuOzBizszN	NYjZSnRXPzJiaB?=	M4rPWIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	Mm\rNlU2OTlzNEi=
KOC7C	NH\QcJhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVzENHloOS1\|MDFOwG0>	M{fVN\|czKGh?	MkPm[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	M3foRVI2PTF7MUS4
HAC2	MlvnR4VtdCCYaXHibYxqfHliQYPzZZk>	MYmxMVMxKM7:TR?=	M4rwe\|czKGh?	M2XpTYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NHKyc3AzPTVzOUG0PC=>
RMG2	MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NHTrfFMyNTNyIN88US=>	NUfOVZFiPDhiaB?=	MWDk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NEm5NlkzPTVzOUG0PC=>
OVISE	NWfnZmoxS2WubDDWbYFjcWyrdImgRZN{[Xl?	NWToSZc6OS1\|MDFOwG0>	MUK0PEBp	Mon2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	Ml;aNlU2OTlzNEi=
SKOV3	NFW5VWRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXuxMVMxKM7:TR?=	MoPUOFghcA>?	NYL2NGE3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MVGyOVUyQTF2OB?=
A2780	M1vXZ2NmdGxiVnnhZoltcXS7IFHzd4F6	Mn6wNU0{OCEQvF2=	Mnv5OFghcA>?	MX7k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MUGyOVUyQTF2OB?=
RMG1	NUnqWY03SXCxcITvd4l{KEG\|c4PhfS=>	NXPqZVQ2OzBizszN	M2jmNlI1KGh?	MV;pcoR2[2W\|IHHwc5B1d3Orcx?=	MkDiNlU2OTlzNEi=
RMG2	MXjBdI9xfG:\|aYOgRZN{e2G7	M3zme\|MxKM7:TR?=	Ml\TNlQhcA>?	NUSyeXlXcW6mdXPld{BieG:ydH;zbZM>	MojoNlU2OTlzNEi=
HCC1806	M3fFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{T2elAuOTBizszN	MkTJOFghcA>?	MV;FR\|UxRTJwOEVihKnDueLCiUCuNFch\|ryP	Mn;1NlUzQTN3N{[=
MDA-MB-231	NIXnNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHrSXhxOC1zMDFOwG0>	NXX0T4pWPDhiaB?=	MkKySWM2OD1zLkGz5qCKyrIkgJmwMlA4KM7:TR?=	NWG0eWtZOjV{OUO1O\|Y>
GL-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLvdW0xNjIkgKOxNFDjiIoQvF2=	MnTBOFghcA>?	M1;s[WlEPTB;OT65NUDPxE1?	M{Dp[lI1QDhzNUC4
CLBL-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3i3d\|AvOeLCk{GwNQKBkc7:TR?=	Mm[4OFghcA>?	NYLXUnd3UUN3ME2zN{4xKM7:TR?=	MYmyOFg5OTVyOB?=
UL-1	M2XOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:3NE4y6oDVMUCw5qCK\|ryP	MoLPOFghcA>?	M1fqVGlEPTB;Nz6wNUDPxE1?	NGPpcXUzPDh6MUWwPC=>
Ema	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfENE4y6oDVMUCw5qCK\|ryP	NHXIOIg1QCCq	NYTLe\|U6UUN3ME21PE44KM7:TR?=	Mnn0NlQ5QDF3MEi=
PANC-1	M4jYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDZbIVpOC1{NTFOwG0>	NEjidpo4OiCq	MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MlXmNlQ2OTl5NUG=
MIA	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorNNE0zPSEQvF2=	NH\QdYY4OiCq	Mlj2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MYeyOFUyQTd3MR?=
AsPC-1	NH;jd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MViwMVI2KM7:TR?=	M{PJNlczKGh?	M{X1WolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MUiyOFUyQTd3MR?=
PANC-1	M1PIRmZ2dmO2aX;uJGF{e2G7	NVHsOZZOOC53IN88US=>	NWna[XlCOjRiaB?=	M4fKU4lvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb\|EwOiCyaH;zdIhwenmuYYTpc47DqA>?	NEPpeGgzPDVzOUe1NS=>
MIA	NHrQbpZHfW6ldHnvckBCe3OjeR?=	NHr0[FMxNjVizszN	NIPyZmIzPCCq	MX3pcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM\|IheGixc4Doc5J6dGG2aX;uxsA>	NIDzd4IzPDVzOUe1NS=>
AsPC-1	NW\Cc5M4TnWwY4Tpc44hSXO\|YYm=	MkPNNE42KM7:TR?=	MWeyOEBp	NUDCbllIcW6qaXLpeJMhSWu2LDDTOmsyNCCjbnSgSZJsOS9{IIDoc5NxcG:{eXzheIlwdsLi	M4nMfFI1PTF7N{Wx
U87MG	M4nafWNmdGxiVnnhZoltcXS7IFHzd4F6	NVSxTIpXOC1{NTFOwG0>	M2K5WFI1NTl4IHi=	M4r4ZYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	NID0V\|IzPDB4NUWyNi=>
SGC7901	M{Plc2Z2dmO2aX;uJGF{e2G7	NF33e5cxNjd3L{GwxsDPxE1?	M1rIUVQ5KGh?	NXS4N2JI\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh	M3:xO\|I{QTF{MkS2
MGC803	MlnPSpVv[3Srb36gRZN{[Xl?	M{Xwe\|AvPzVxMUFCpO69VQ>?	MnzLOFjDqGh?	NHzLN2Zl\WO{ZXHz[ZMheC2Da4SgLHNmeiB2N{OpMEBxNUeVS{ROtkApW2W{IEmpMEBidmRiQz3NXWMhdGW4ZXzzxsA>	NHvmWJUzOzlzMkK0Oi=>
TykNu	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVLpZZYxUUN3ME2zMlUh\|ryP	NX7ZTm0xOjN6N{ewNVI>
TykNuR	NVz4PWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2rUe2lEPTB;NT61JO69VQ>?	M{nQUVI{QDd5MEGy
M41	NXjvdGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml\TTWM2OD1{ND63JO69VQ>?	NHS2[VIzOzh5N{CxNi=>
M41R	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVnJR\|UxRTF7Lkig{txO	M3zwNFI{QDd5MEGy
OVCAR8	NGKzdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1HGOWlEPTB;M{GuNUDPxE1?	M331d\|I{QDd5MEGy
HeyA8	M4DkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3XyN2lEPTB;MkSuN{DPxE1?	M4LURlI{QDd5MEGy
A2780CP	NEC2c2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2fPPWlEPTB;Nz62JO69VQ>?	MnvFNlM5PzdyMUK=
OVCAR5	M{\zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUHJR\|UxRTZwNzFOwG0>	MYmyN\|g4PzBzMh?=
A2780S	NHHjUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH;TTIVKSzVyPUG0MlUh\|ryP	Mly4NlM5PzdyMUK=
MCAS	M3LJR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlvDTWM2OD1zMj61JO69VQ>?	NEXyPWIzOzh5N{CxNi=>
NCI-H727	MojmR4VtdCCYaXHibYxqfHliQYPzZZk>	MYWwMVExOCEQvF2=	NYDZOIVNOjRxN{KgbC=>	NG\OSYpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	M3TVflIzPDl7NEO3
GOT1	NXnpfo04S2WubDDWbYFjcWyrdImgRZN{[Xl?	Mlr4NE0yODBizszN	NVfGbVJ4OjRxN{KgbC=>	Mmr6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	Ml7LNlI1QTl2M{e=
BON1	MoP0R4VtdCCYaXHibYxqfHliQYPzZZk>	NFjYeZIxNTFyMDFOwG0>	NVfBd4ZoOjRxN{KgbC=>	M2fE[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	Mkj5NlI1QTl2M{e=
BON1	NF;6fWVCeG:ydH;zbZMhSXO\|c3H5	MnG4NE0yOCEQvF2=	NIHTVmszPCCq	Mn\GbY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	MWSyNlQ6QTR\|Nx?=
BON1	NYHRN\|BETnWwY4Tpc44hSXO\|YYm=	MljVO{42NzFyIN88US=>	NVPrO5ltQCCq	NYHsfVFn\GWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKHSqZTDhcpRqNWGyb4D0c5Rq[yCycn;0[YlveyCEQ1yyJIFv\CCEY3ytXGw>	MYWyNlQ6QTR\|Nx?=
Kasumi-1	MnLDR4VtdCCYaXHibYxqfHliQYPzZZk>	M1vHSFAuOjBizszN	MljoNlQwPDhiaB?=	Mmfq[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	Mn31NlI1ODd{Mki=
HL-60	MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NVPzXGE3OC1{MDFOwG0>	MoLxNlQwPDhiaB?=	NVnURmhK\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	MYKyNlQxPzJ{OB?=
Kasumi-1	NFf4XodCeG:ydH;zbZMhSXO\|c3H5	NVezNIZwOTBizszN	Ml71NlQhcA>?	NF3PZpFqdmS3Y3XzJIFxd3C2b4Ppdy=>	MmnqNlI1ODd{Mki=
HL-60	MmS1RZBweHSxc3nzJGF{e3OjeR?=	MXyxNEDPxE1?	NUjlXXhzOjRiaB?=	NXrrdolzcW6mdXPld{BieG:ydH;zbZM>	M{PlbFIzPDB5MkK4
Kasumi-1	MkHVSpVv[3Srb36gRZN{[Xl?	M3LCVlIvPS93L{GwJO69VQ>?	NX;sVXdiOjRiaB?=	NWHKb2U{\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy\|wrDkc5NmNWSncHXu[IVvfGy7	MYWyNlQxPzJ{OB?=
HL-60	MX;GeY5kfGmxbjDBd5NigQ>?	NGDnS\|AzNjVxNT:xNEDPxE1?	NWD4bVdnOjRiaB?=	M2fi[oRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>?	NYnPSXd4OjJ2MEeyNlg>
Kasumi-1	M3n2TGZ2dmO2aX;uJGF{e2G7	MVOyMlUwPS9zMDFOwG0>	NWfzTodDOjRiaB?=	MV\pcoR2[2W\|IITo[UBxcG:\|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MmH1NlI1ODd{Mki=
HL-60	NGjqfI5HfW6ldHnvckBCe3OjeR?=	M2TkdVIvPS93L{GwJO69VQ>?	MnjJNlQhcA>?	M4TxU4lv\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCMTluxM\|IhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M{\YPVIzPDB5MkK4
K562	NYnOelJDTnWwY4Tpc44hSXO\|YYm=	M2nTblIxKM7:TR?=	Mn:4OFghcA>?	MojSbY5lfWOnczDheZRweGijZ4pCpC=>	M3[3b\|IzPDB5MkK4
OCUT1	MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1r1ZlAvOS1\|IN88US=>	NV;PNoZNPSCm	MonibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MXiyNlA6ODJ5MR?=
K1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVX3XJpLOC5zLUOg{txO	M2rOO\|Uh\A>?	MYTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MmH0NlIxQTB{N{G=
OCUT1	NFXxSJdHfW6ldHnvckBCe3OjeR?=	MV:zJO69dQ>?	NVLXXXBwOjRiaB?=	MnLtZ4F2e2W\|IHGg[JJidWG2aXOgbY5kemWjc3WgbY4hTzJxTTDwbIF{\Q>?	M3O5TFIzODlyMkex
CaOV3	Mly0R4VtdCCYaXHibYxqfHliQYPzZZk>	MV2xM\|UwOTBizszN	M3[5U\|Q5KGh?	NWLidnpD\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyJINwfHKnYYTl[EB4cXSqIIDhZ4xqfGG6ZXy=	MkntNlE4PzVyNUS=
SKOV3	M1HCZWN6fG:2b4jpZ4l1gSCDc4PhfS=>	MVu1JO69VQ>?	MX60PEBp	NH[2d\|ZmdmijbnPld{Bx[WOuaYThfIVtKGmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh	MViyNVc4PTB3NB?=
A2780	MXPDfZRwfG:6aXPpeJkhSXO\|YYm=	MVS1JO69VQ>?	NV31NIxNPDhiaB?=	M1jYXYVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>	NFrLT3AzOTd5NUC1OC=>
HT-29	MWfDfZRwfG:6aXPpeJkhSXO\|YYm=	M2T2[lUh\|ryP	M1;UN\|Q5KGh?	NWTQ[VBV\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>?	M2nXcFIyPzd3MEW0
A498	NH3SdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojJNE01OCEQvF2=	MonRO\|IhcA>?	NUH4S25zcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NILnO2QzOTZ2NEC1NC=>
CAKI-1	NWXPdXpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PpVVAuPDBizszN	MW[3NkBp	Ml3XTWM2OH5zMDFOwG0>	NWDVd4lPOjF4NESwOVA>
769-P	M2DiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXKwMVQxKM7:TR?=	MofHO\|IhcA>?	MYjJR\|UxhjVvMUCg{txO	M{n0XFIyPjR2MEWw
786-0	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYOwMVQxKM7:TR?=	MmfQO\|IhcA>?	NXXKNWlyUUN3MI61JO69VQ>?	MlW4NlE3PDRyNUC=
786-O	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorRNE0zOCEQvF2=	MWK3NkBp	M4LiOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NIDYWZMzOTZ2NEC1NC=>
CAKI-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmS5NE0zOCEQvF2=	MXu3NkBp	MkLPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M{\QR\|IyPjR2MEWw
769-P	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWiwMVIxKM7:TR?=	M4jYVVczKGh?	MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NGXWd2YzOTZ2NEC1NC=>
A498	MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUSwMVIxKM7:TR?=	NFexc2I4OiCq	M1TnWIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MorRNlE3PDRyNUC=
CWR22RV1	NUTwNG5US2WubDDWbYFjcWyrdImgRZN{[Xl?	NWXUdZVxOTBizszN	NHniOpAzPCCq	MlPZbY5kemWjc3XzJJNmdnOrdHn2bZR6KG:oIHj1cYFvKEOZUkKyVnYyKGOnbHzzJJRwKHKjZHnheIlwdg>?	MYmyNVQ6PjJ5Mx?=
CWR22RV1	M3XqZ2Fxd3C2b4Ppd{BCe3O\|YYm=	MVGxNEDPxE1?	Mnj3NlQhcA>?	NE\zeXlmdmijbnPld{Bz[WSrYYTpc44hcW6mdXPl[EBieG:ydH;zbZM>	NH6yXpYzOTR7NkK3Ny=>
CWR22RV1	MlvHSpVv[3Srb36gRZN{[Xl?	NFrWTm02KM7:TR?=	M{nzelI1KGh?	NVjIXZloemWmdXPl[EBxcG:\|cHjvdplt[XSrb36gc4YhSWu2IIPp[45q\mmlYX70cJk>	MYKyNVQ6PjJ5Mx?=
HepG2	M3vpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnkO482NzFyL{KwM\|QxKM7:TR?=	MmjDNlQwPDhxN{KgbC=>	MlSwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NFTid2szODh2MkSyOS=>
Bel-7402	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LMVlUwOTBxMkCvOFAh\|ryP	Mn;6NlQwPDhxN{KgbC=>	Ml3zbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MX[yNFg1OjR{NR?=
HepG2	Moi4SpVv[3Srb36gRZN{[Xl?	NYfTSlQ2PS9zMD:yNEDPxE1?	NInR[mQzPCCq	MnvVdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn	MlezNlA5PDJ2MkW=
Bel-7402	NIXz[IRHfW6ldHnvckBCe3OjeR?=	MWO1M\|ExNzJyIN88US=>	MXOyOEBp	MnjSdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn	NFn3TWYzODh2MkSyOS=>
HepG2	MVvBdI9xfG:\|aYOgRZN{e2G7	MlTiOU8yOC9{MDFOwG0>	NVfVRpo3OjRxNEigbC=>	M1P0Xolv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW=	MXuyNFg1OjR{NR?=
Bel-7402	MmHlRZBweHSxc3nzJGF{e3OjeR?=	NHfIOFM2NzFyL{KwJO69VQ>?	NFv3TmwzPC92ODDo	NGDDOlVqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:\|dYLl	MXSyNFg1OjR{NR?=
OAW-42	M4jzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUiwMVQxKM7:TR?=	MXi3NuKhcA>?	NE\zSmVKSzVyfkGwJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M4f4RlIxPDB3Mkm2
PA-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrMNE01OCEQvF2=	NV;IXVBbPzMEoHi=	M4rqUmlEPTC-MkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NFe5SIgzODRyNUK5Oi=>
SKOV3	NH;5S21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{S2XFAuPDBizszN	NIX2U4U4OsLiaB?=	MlrjTWM2OH5\|MDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MWmyNFQxPTJ7Nh?=
A2780	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\iW\|AuOjBizszN	MXq0PE84OiCq	NWrXVow2UUN3MNMgQeKhO8Lizszt	NH\5UGkzODRyNUK5Oi=>
A2780cis	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYSwMVIxKM7:TR?=	MW[0PE84OiCq	Mn;0TWM2OMLiPdMgOuKh\|ryv	NU\jNo5JOjB2MEWyPVY>
SKW6.4	NU[xN\|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVGyMVExyqEQvF2=	NX7PWnR2PDkEoHi=	NVnyenVmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NVfSNI45OjBzM{C5OlA>
MAVER	MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zMblIuOTEEoN88US=>	MknsOFjDqGh?	Ml\obY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MojONlAyOzB7NkC=
BJAB	MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDS[pYzNTFywrFOwG0>	NVfyV\|RDPDkEoHi=	NEnnNGZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M3;nbFIxOTNyOU[w
OCI	NFLIVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:3VoVoOi1zMNMg{txO	M2DsVFQ5yqCq	MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MWKyNFE{ODl4MB?=
MOLM	M3r6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4L2dVIuOTEEoN88US=>	MVi0POKhcA>?	MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NGPwVZozODF\|MEm2NC=>
HL-60	NVTLbFZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWG4c\|M6Oi1zMNMg{txO	MmXjOFjDqGh?	MUPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	Mo\lNlAyOzB7NkC=
SKW6.4	NGTWeIRCeG:ydH;zbZMhSXO\|c3H5	MXexNOKh\|ryP	NYXa[FlYOjRxNEigbC=>	NHyxPZdqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	Mn65NlAyOzB7NkC=
MAVER	NW[4dW1GSXCxcITvd4l{KEG\|c4PhfS=>	MVixNOKh\|ryP	MmHlNlQwPDhiaB?=	MXfpcoR2[2W\|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7	NXrPOnlDOjBzM{C5OlA>
BJAB	NEW3W5dCeG:ydH;zbZMhSXO\|c3H5	MVGxNOKh\|ryP	NIHXPVMzPC92ODDo	MVnpcoR2[2W\|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7	MmjBNlAyOzB7NkC=
OCI	NGTzSWdCeG:ydH;zbZMhSXO\|c3H5	NXHocnUxOTEEoN88US=>	NWLtV41xOjRxNEigbC=>	M37YdYlv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm=	M2XjfVIxOTNyOU[w
MOLM	NFu0T5pCeG:ydH;zbZMhSXO\|c3H5	MmP6NVDDqM7:TR?=	NGOxVmczPC92ODDo	NHLvXY1qdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	NVH1[ZBlOjBzM{C5OlA>
HL-60	NHrIXnpCeG:ydH;zbZMhSXO\|c3H5	M3noUFExyqEQvF2=	NVrxRpgzOjRxNEigbC=>	NFjCdlFqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	NVfI[mg{OjBzM{C5OlA>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-S6K1 / S6K1 ; PubMed: 25519148 Mol Cancer Res The effect of perifosine on AKT-mTOR activation in vitro. RMG1 and RMG2 cells were treated with 0, 3, 10, 30 or 50 μM perifosine for 6 h in the presence of 10% FBS. Cells were harvested, and equivalent amounts (30 μg) of protein were subjected to SDS-PAGE and blotted with anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-S6K1 (Thr389), anti-S6K1, or anti-β-actin antibodies. PARP; PubMed: 25519148 Mol Cancer Res Perifosine induces apoptosis. RMG1 and RMG2 cells were treated with or without 30 μM perifosine for 24 h. Cells were harvested, and the effect of perifosine was evaluated by western blotting p-mTOR / mTOR / Raptor / Rictor / p-p70S6K / p70S6K / p-4EBP1 / 4EBP1 / c-Myc / Cyclin D1; PubMed: 19920197 Cancer Res The indicated cell lines were treated with the given concentrations of perifosine (PRFS) for 8 h. p-PDK1 / p-GSK3α/β / p-S6R ; PubMed: 17761832 Blood BCWM.1 cells were cultured with perifosine for 6 hours with doses that ranged from 2 to 20 μM. Whole cell lysates were subjecting to Western blotting using anti–p-Akt ser473, -Akt, –p-PDK1, –p-GSK3α/β, –p-S6R, and α-tubulin antibodies.	25519148 19920197 17761832
Growth inhibition assay	Cell viability; PubMed: 28332584 Sci Rep Cell survival measured by MTT assay and IC50 of perifosine in a panel of eleven human cancer cells.	28332584

In vivo

Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. ^[2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. ^[3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. ^[5]

Protocol

Kinase Assay:^[3]	- Collapse Akt kinase assay: MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:^[2]	- Collapse Cell lines: Human glioma cell lines Concentrations: 0, 15, 30 and 45 μM Incubation Time: 48 hours Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader. (Only for Reference)
Animal Research:^[3]	- Collapse Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old). Dosages: 250 mg/kg/wk or 36 mg/kg/d Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	8 mg/mL (17.32 mM)
	DMSO	Insoluble
	Ethanol	'15 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Perifosine (KRX-0401) SDF

Molecular Weight	461.66
Formula	C₂₅H₅₂NO₄P
CAS No.	157716-52-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NSC639966, D21266
Smiles	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01224730	Completed	Drug: perifosine	Cancer	AEterna Zentaris	January 24 2012	Phase 1
NCT01049841	Completed	Drug: perifosine + temsirolimus	Pediatric Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|NATL COMP CA NETWORK\|Pfizer\|AEterna Zentaris	January 2010	Phase 1
NCT01048580	Completed	Drug: Perifosine\|Drug: Capecitabine	Colon Cancer	AEterna Zentaris\|SCRI Development Innovations LLC	October 2009	Phase 1
NCT00776867	Completed	Drug: perifosine	Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|AEterna Zentaris	October 2008	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Selective Akt Inhibitor

CCT128930 : AKT2-selective, IC50=6 nM.
Most Potent Akt Inhibitor

AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.
Akt Inhibitor in Clinical Trial

Ipatasertib (GDC-0068) : Phase II for Prostate Cancer and Gastric Cancer.
Newest Akt Inhibitor

AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

Afuresertib (GSK2110183) ^New

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
AT13148 ^New

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
SC79 ^New

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
Capivasertib (AZD5363)

Capivasertib (AZD5363) potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Ipatasertib (GDC-0068)

Ipatasertib (GDC-0068, RG7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.
GSK690693

GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family with IC50 of 50 nM and 81 nM, respectively. GSK690693 affects Unc-51-like autophagy activating kinase 1 (ULK1) activity, robustly inhibits STING-dependent IRF3 activation. Phase 1.
A-674563

A-674563 is an Akt1 inhibitor with K_i of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.
Triciribine

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Honokiol

Honokiol (NSC 293100) is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Perifosine (KRX-0401)